ClinicalTrialsFinder
RecruitingPhase 4NCT03821857

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

Sponsor

Mayo Clinic

Enrollment

614 participants

Start Date

Jun 27, 2019

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

Eligibility

Sex: FEMALEMin Age: 60 Years

Inclusion Criteria9

  • Mayo Clinic Rochester-
  • Women who previously participated in this study
  • Currently aged 60 years and older
  • More than six months post chemotherapy or major surgery requiring general anesthesia
  • Willing and able to sign informed consent
  • African American Women
  • Currently aged 60 years and older
  • More than six months post chemotherapy or major surgery requiring general anesthesia
  • Willing and able to sign informed consent

Exclusion Criteria9

  • Not able to read and speak English
  • In hospice
  • Claustrophobic
  • If undergoing Tau imaging, cannot have QT Prolongation
  • Mayo Clinic Jacksonville-
  • Not able to read and speak English
  • In hospice
  • Claustrophobic
  • If undergoing Tau imaging, cannot have QT Prolongation

Interventions

DRUG18-F-Flortaucipir

Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

Locations(2)

Mayo Clinic

Jacksonville, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03821857

Related Trials

Novel Augmentation of DAOIB and Antioxidant for Early Dementia

NCT064675391 location

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229241 locations

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT041233141 location

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT071782101 location

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732157 locations